Dominik Brucher
Overview
Explore the profile of Dominik Brucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freitag P, Kolibius J, Wieboldt R, Weber R, Hartmann K, van Gogh M, et al.
Mol Ther Oncol
. 2024 Jul;
32(3):200821.
PMID: 39021370
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration...
2.
Thalmann L, Martin-Gonzalez N, Brucher D, Pluckthun A, de Pablo P, Suomalainen M, et al.
Hum Gene Ther
. 2024 Feb;
35(5-6):163-176.
PMID: 38386500
Delivering vectorized information into cells with the help of viruses has been of high interest to fundamental and applied science, and bears significant therapeutic promise. Human adenoviruses (HAdVs) have been...
3.
Freitag P, Kaulfuss M, Fluhler L, Mietz J, Weiss F, Brucher D, et al.
Mol Ther Methods Clin Dev
. 2023 Apr;
29:120-132.
PMID: 37007608
Clinical success in T cell therapy has stimulated widespread efforts to increase safety and potency and to extend this technology to solid tumors. Yet progress in cell therapy remains restricted...
4.
Schellhorn S, Brucher D, Wolff N, Schroer K, Sallard E, Mese K, et al.
Hum Gene Ther
. 2023 Feb;
34(5-6):203-216.
PMID: 36802735
Oncolytic viruses are a promising technology to attack cancer cells and to recruit immune cells to the tumor site. Since the Lipocalin-2 receptor (LCN2R) is expressed on most cancer cells,...
5.
Freitag P, Brandl F, Brucher D, Weiss F, Dreier B, Pluckthun A
Bioconjug Chem
. 2022 Aug;
33(9):1595-1601.
PMID: 35944553
Efficient and cell-specific delivery of DNA is essential for the effective and safe use of gene delivery technologies. Consequently, a large variety of technologies have been developed and applied in...
6.
Kirchhammer N, Trefny M, Natoli M, Brucher D, Smith S, Werner F, et al.
Sci Transl Med
. 2022 Jul;
14(653):eabm9043.
PMID: 35857639
T cell-directed cancer immunotherapy often fails to generate lasting tumor control. Harnessing additional effectors of the immune response against tumors may strengthen the clinical benefit of immunotherapies. Here, we demonstrate...
7.
Smith S, Schubert R, Simic B, Brucher D, Schmid M, Kirk N, et al.
Proc Natl Acad Sci U S A
. 2021 May;
118(21).
PMID: 34001602
The goal of cancer-drug delivery is to achieve high levels of therapeutics within tumors with minimal systemic exposure that could cause toxicity. Producing biologics directly in situ where they diffuse...
8.
Brucher D, Kirchhammer N, Smith S, Schumacher J, Schumacher N, Kolibius J, et al.
Mol Ther Methods Clin Dev
. 2021 Mar;
20:572-586.
PMID: 33665227
Adenovirus-mediated combination gene therapies have shown promising results in vaccination or treating malignant and genetic diseases. Nevertheless, an efficient system for the rapid assembly and incorporation of therapeutic genes into...
9.
Picecchi D, Bertram K, Brucher D, Bauer M
Swiss Med Wkly
. 2020 Dec;
150:w20355.
PMID: 33378542
Currently, a major focus of biomedical research and clinical application are the so-called advanced therapy medicinal products (ATMPs), which are highly complex medicines that enable the targeted and personalised treatment...
10.
Brucher D, Franc V, Smith S, Heck A, Pluckthun A
MAbs
. 2020 Jul;
12(1):1792084.
PMID: 32643525
Gene therapy approaches now allow for the production of therapeutic antibodies by healthy or cancerous human tissues directly , and, with an increasing number of gene delivery methods available, the...